Yuriy Ostapenko

Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma

Ghassan K. Abou‐Alfa, George Lau, Masatoshi Kudo et al. · NEJM Evidence · 2022 · 1.4K citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

Jonathan W. Goldman, Mikhail Dvorkin, Yuanbin Chen et al. · The Lancet Oncology · 2020 · 687 citations · Full text

Medicine, Oncology, Pharmacology +14

Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial

Yelena Y. Janjigian, Akihito Kawazoe, Yuxian Bai et al. · The Lancet · 2023 · 467 citations

Medicine, Oncology, Pharmacology +17

Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC

Lorenza Rimassa, Stephen L. Chan, Bruno Sangro et al. · Journal of Hepatology · 2025 · 109 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +6

Pembrolizumab Plus Chemotherapy Versus Chemotherapy as Perioperative Therapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer: Final Analysis of the Randomized, Phase III KEYNOTE-585 Study

Sun Young Rha, Lucjan Wyrwicz, Nina Karaseva et al. · Journal of Clinical Oncology · 2025 · 29 citations

Medicine, Oncology, Perioperative Medicine +17